Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the <scp>C</scp>ardio‐<scp>O</scp>ncology <scp>S</scp>tudy <scp>G</scp>roup of the <scp>H</scp>eart <scp>F</scp>ailure <scp>A</scp>ssociation of the <scp>E</scp>uropean <scp>S</scp>ociety of <scp>C</scp>ardiology in collaboration with the <scp>I</scp>nternational <scp>C</scp>ardio‐<scp>O</scp>ncology <scp>S</scp>ociety
-
- Alexander R. Lyon
- Cardio‐Oncology Service Royal Brompton Hospital and Imperial College London UK
-
- Susan Dent
- Duke Cancer Institute Duke University Durham NC USA
-
- Susannah Stanway
- Breast Unit Royal Marsden Hospital Surrey UK
-
- Helena Earl
- Department of Oncology University of Cambridge and NIHR Cambridge Biomedical Research Centre Cambridge UK
-
- Christine Brezden‐Masley
- Division of Medical Oncology, Sinai Health System Mount Sinai Hospital Toronto Canada
-
- Alain Cohen‐Solal
- UMR‐S 942, Paris University, Cardiology Department, Lariboisiere Hospital, AP‐HP Paris France
-
- Carlo G. Tocchetti
- Department of Translational Medical Sciences and Interdepartmental Center for Clinical and Translational Research (CIRCET) Federico II University Naples Italy
-
- Javid J. Moslehi
- Cardio‐Oncology Program, Department of Medicine Vanderbilt University Medical Center Nashville TN USA
-
- John D. Groarke
- Cardio‐Oncology Program, Brigham & Women's Hospital Harvard Medical School Boston MA USA
-
- Jutta Bergler‐Klein
- Department of Cardiology Medical University of Vienna Vienna Austria
-
- Vincent Khoo
- Department of Clinical Oncology Royal Marsden Hospital and Institute of Cancer Research London UK
-
- Li Ling Tan
- Department of Cardiology, National University Heart Centre, Singapore National University Health System Singapore Singapore
-
- Markus S. Anker
- Division of Cardiology and Metabolism, Department of Cardiology, Charité and Berlin Institute of Health Center for Regenerative Therapies (BCRT) and DZHK (German Centre for Cardiovascular Research), partner site Berlin and Department of Cardiology Charité Campus Benjamin Franklin Berlin Germany
-
- Stephan von Haehling
- Department of Cardiology and Pneumology University of Goettingen Medical Center Goettingen Germany
-
- Christoph Maack
- Comprehensive Heart Failure Center University Clinic Würzburg Würzburg Germany
-
- Radek Pudil
- First Department of Medicine – Cardioangiology, Charles University Prague Medical Faculty and University Hospital Hradec Kralove Prague Czech Republic
-
- Ana Barac
- MedStar Heart and Vascular Institute Georgetown University Washington DC USA
-
- Paaladinesh Thavendiranathan
- Ted Rogers Program in Cardiotoxicity Prevention and Joint Division of Medical Imaging, Peter Munk Cardiac Center, Toronto General Hospital University Health Network, University of Toronto Toronto Canada
-
- Bonnie Ky
- University of Pennsylvania Philadelphia PA USA
-
- Tomas G. Neilan
- Cardio‐Oncology Program, Division of Cardiology, Department of Medicine, Massachusetts General Hospital Harvard Medical School Boston MA USA
-
- Yury Belenkov
- Sechenov Medical University Moscow Russia
-
- Stuart D. Rosen
- Cardio‐Oncology Service Royal Brompton Hospital and Imperial College London UK
-
- Zaza Iakobishvili
- Department of Community Cardiology, Tel Aviv Jaffa District, Clalit Health Fund and Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel
-
- Aaron L. Sverdlov
- School of Medicine and Public Health, University of Newcastle and “Cancer and the Heart” Program Hunter New England LHD Newcastle Australia
-
- Ludhmila A. Hajjar
- Cardio‐Oncology, Department of Cardio‐Pneumology University of São Paulo São Paulo Brazil
-
- Ariane V.S. Macedo
- Santa Cardio‐Oncology, Santa Casa de São Paulo and Rede Dor São Luiz São Paulo Brazil
-
- Charlotte Manisty
- Barts Heart Centre and University College London London UK
-
- Fortunato Ciardiello
- Department of Precision Medicine Luigi Vanvitelli University of Campania Naples Italy
-
- Dimitrios Farmakis
- University of Cyprus Medical School Nicosia Cyprus
-
- Rudolf A. de Boer
- Department of Cardiology University of Groningen, University Medical Center Groningen Groningen The Netherlands
-
- Hadi Skouri
- Cardiology Division, Internal Medicine Department, American University of Beirut Medical Center Beirut Lebanon
-
- Thomas M. Suter
- Department of Cardiology, Bern University Hospital, Inselspital University of Bern Bern Switzerland
-
- Daniela Cardinale
- Cardioncology Unit, European Institute of Oncology IRCCS Milan Italy
-
- Ronald M. Witteles
- Stanford University School of Medicine Stanford CA USA
-
- Michael G. Fradley
- University of Pennsylvania Philadelphia PA USA
-
- Joerg Herrmann
- Department of Cardiovascular Diseases Mayo Clinic Rochester MN USA
-
- Robert F. Cornell
- Vanderbilt University Medical Center Nashville TN USA
-
- Ashutosh Wechelaker
- National Amyloidosis Centre University College London London UK
-
- Michael J. Mauro
- Memorial Sloan Kettering Cancer Center New York NY USA
-
- Dragana Milojkovic
- Department of Haematology Hammersmith Hospital, Imperial College London UK
-
- Hugues de Lavallade
- Department of Haematological Medicine King's College Hospital London UK
-
- Frank Ruschitzka
- University Heart Center, Department of Cardiology University Hospital Zurich Zurich Switzerland
-
- Andrew J.S. Coats
- University of Warwick Warwick UK
-
- Petar M. Seferovic
- Faculty of Medicine and Serbian Academy of Sciences and Arts University of Belgrade Belgrade Serbia
-
- Ovidiu Chioncel
- Emergency Institute for Cardiovascular Diseases ‘Prof. C.C. Iliescu’ Bucharest Romania
-
- Thomas Thum
- Institute of Molecular and Translational Therapeutic Strategies Hannover Medical School Hannover Germany
-
- Johann Bauersachs
- Department of Cardiology and Angiology Hannover Medical School Hannover Germany
-
- M. Sol Andres
- Cardio‐Oncology Service Royal Brompton Hospital and Imperial College London UK
-
- David J. Wright
- Liverpool Centre for Cardiovascular Science Liverpool Heart and Chest Hospital Liverpool UK
-
- Teresa López‐Fernández
- Cardiology Service, Cardio‐Oncology Unit La Paz University Hospital and IdiPAz Research Institute, Ciber CV Madrid Spain
-
- Chris Plummer
- Department of Cardiology The Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University Newcastle UK
-
- Daniel Lenihan
- Cardio‐Oncology Center of Excellence Washington University in St Louis St Louis MO USA
抄録
<jats:p>This position statement from the Heart Failure Association of the European Society of Cardiology Cardio‐Oncology Study Group in collaboration with the International Cardio‐Oncology Society presents practical, easy‐to‐use and evidence‐based risk stratification tools for oncologists, haemato‐oncologists and cardiologists to use in their clinical practice to risk stratify oncology patients prior to receiving cancer therapies known to cause heart failure or other serious cardiovascular toxicities. Baseline risk stratification proformas are presented for oncology patients prior to receiving the following cancer therapies: anthracycline chemotherapy, HER2‐targeted therapies such as trastuzumab, vascular endothelial growth factor inhibitors, second and third generation multi‐targeted kinase inhibitors for chronic myeloid leukaemia targeting BCR‐ABL, multiple myeloma therapies (proteasome inhibitors and immunomodulatory drugs), RAF and MEK inhibitors or androgen deprivation therapies. Applying these risk stratification proformas will allow clinicians to stratify cancer patients into low, medium, high and very high risk of cardiovascular complications prior to starting treatment, with the aim of improving personalised approaches to minimise the risk of cardiovascular toxicity from cancer therapies.</jats:p>
収録刊行物
-
- European Journal of Heart Failure
-
European Journal of Heart Failure 22 (11), 1945-1960, 2020-08-06
Wiley